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Introduction
This report reflects the consensus of the Clinical and Translational 
Science Awards (CTSA) Consortium Scientific Review Committee 
(SRC) Consensus Working Group, responding to the charge to 
propose a framework for scientific review processes of human 
participant research protocols at CTSA institutions. The objectives 
of the proposed SRC process are to assure the scientific validity and 
feasibility of human research protocols and to uphold institutions’ 
missions of promoting excellence in research. The Working Group 
envisions this as a committee process, and the term SRC is used 
throughout, but it is understood that the exact configuration of 
review will vary according to institutional circumstances. In any 
case, there was strong consensus on the requirement for the SRC 
process, criteria for protocol selection for review, and criteria for 
the process of review as described in this report.
Research involving human participants must comply with 
well-recognized ethical and regulatory precepts and processes.1 
An important ethical requirement is that a research project 
involving humans must have a scientifically valid study design and 
analytic plan while being operationally feasible. This fundamental 
concept is essential to providing a reasonable chance of generating 
new knowledge. Human studies that are improperly designed, or 
cannot achieve their proposed aims (e.g., because of inadequate 
sample size) are, by definition, unethical as they impose risks and 
burden on study subjects without a likely benefit to the participants 
or society. Given the breadth of the issues that must be adjudicated 
by an institutional review board (IRB) in approving a study, and 
given the specialized expertise and discussion that may be needed 
to judge study design, plan, and feasibility, a focused SRC review 
should be conducted prior to, but integral to, full IRB review. This 
should help ensure that a study meets acceptable standards of 
scientific rigor and feasibility. With an SRC process in place, the 
quality of research will be more directly assessed and supported, 
while the work of the IRB made more efficient.
This approach of having SRC assessment prior to full IRB 
review is aligned with the IRB mandate to assure ethical conduct 
of human research. The exact relation and interaction of the SRC, 
particularly with an IRB, will vary based on individual institutional 
structures and functions related to human participant research. 
Even though some variations due to institutional circumstances 
(e.g., differences in protocol submission procedures and specific 
roles of SRC members) might be necessary, the SRC process 
described in this report should be part of the institutional review 
process for human research protocols.
Despite the important intent, a potential detriment to the 
overall clinical research enterprise would be if the SRC process 
degraded institutional efficiency and timeliness. To promote 
assessment of such an effect and for efficiency, institutional 
information technology infrastructures should facilitate 
SRC processes and communication among the SRC, IRB, 
and the principal investigator (PI; see IT recommendations 
in Appendix 1). To detect potentially deleterious effects, 
institutions should monitor the SRC process for burden of 
implementation, effect on protocol quality and feasibility, 
and efficiency of the review process (i.e., time for SRC and 
IRB review, net investigator time to make revisions). Specific 
metrics will need to be tested in an anticipated pilot study and 
reported separately. The informatics infrastructure should 
facilitate automated capture of time-based metrics.
Institutional Support for the SRC Process and Roles  
of CTSA
Institutions with National Institutes of Health (NIH) sponsored 
CTSAs should have study design and statistical consultation 
available for investigators to provide clinical research education 
and design assistance for new investigators and others needing 
help. In particular, CTSAs should provide such assistance to those 
funded by the CTSA, such as pilot awards, T, and K awards, even 
prior to being referred to the SRC and IRB. Institutional policies 
should include submission of reviewer feedback from that review 
to the SRC and/or IRB. Institutions may choose to have pre-SRC 
review of all protocols (including those not funded by a CTSA) 
to address the needs of PIs who need study design and related 
assistance prior to, or during, the SRC process. An example of such 
a process is provided in Figure A.1A, Scientific Review at CTSA 
Institutions (for the full Figure A.1, see Appendix 2).
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Multisite Research
In many cases for multisite clinical studies, external funders 
complete a full peer-review of protocols before engaging study 
sites. In these cases, the SRC screening process will determine 
whether there was prior adequate peer review. Because multisite 
clinical studies may use a central IRB (including reliance and other 
centralized models) rather than depend on individual institutional 
review, given the link of SRC and IRB review, SRC review may 
not be necessary at each study site. In these cases, the SRC 
related to the central or relied-upon IRB should be responsible 
for reviewing scientific feasibility. However, although this single 
SRC process would assess scientific quality and general feasibility, 
policies at local institutions should include an assessment of local 
operational feasibility of the study site, available resources, and 
determination that the PI has the necessary skills, experience, and 
time to successfully complete the study. On the occasion that the 
relied-upon IRB does not have a SRC, local institutional policies 
should include a SRC process to ensure scientific validity.
Criteria for Selection for SRC Review
All human participant research should be considered for review 
by a SRC prior to IRB submission. However, the degree of review 
will vary based on the type of research, its needs, and institutional 
factors. We suggest a multipath approach to review that will 
start with determining whether a research protocol is potentially 
exempt from SRC review. This determination should be based 
on such features as whether it has already undergone substantial 
peer review, whether it was an investigator-initiated study that 
has not had extensive vetting, and other factors (See Figure A.1B). 
SRC Review Process. For the full Figure A.1, see Appendix 2).
For example, SRC review will be appropriate for protocols 
that have not already received full peer review, which would 
include (but not be limited to) investigator-initiated projects, 
pilot projects, clinical trial protocols generated by those 
supported by T or K awards or other trainees, by foundations, or 
by pharmaceutical, and biotech companies. If a protocol has not 
received adequate peer review, it should not be exempt from SRC 
review (Path 1 in Figure A.1B). These protocols either proceed 
directly to the SRC for review, or prior to full review, to the SRC 
screener. The screener of the SRC may return the protocol to the 
PI for minor revisions (e.g., clarification and/or responses to SRC 
review points) or for major revisions (i.e., recommendation for 
study design assistance). Once initial questions for the PI are 
addressed, the protocol is sent to the SRC to determine whether 
it is ready for IRB review. With SRC approval, the protocol will 
proceed to the IRB. If the protocol is still not ready for IRB 
review, the protocol will be returned to the PI with additional 
comments and suggestions, and resubmitted to the SRC once 
revisions are made.
Although research protocols with prior adequate peer 
review should be considered for exemption from SRC review, 
some protocols may raise a specific concern that needs to be 
addressed by the PI (Path 2 in Figure A.1B). In this regard, it 
should be noted that review of a research proposal, for example, 
by NIH, is not necessarily the same as review of a research protocol 
from the SRC perspective; the former often does not have the 
details of study processes and analysis. Prior adequate review 
must be of the protocol. When warranted, exemptions based on 
prior adequate review will limit redundant reviews, duplication 
of effort, delays, and bureaucratic burden. Protocols determined 
as exempt from SRC review will be submitted directly to the 
IRB (Path 3 in Figure A.1B). Types of research protocols that 
will usually meet criteria for exemption will have already had 
significant scientific and feasibility review, as determined by the 
SRC chair and/or an equivalent person based on institutional 
policies. Examples of protocols that could potentially be exempt 
from SRC review may include:
•	 	 Research	protocols	 that	have	been	subjected	 to	scientific	
review by a CTSA process, such as for pilot awards or protocols 
generated by K or T awardees that have been reviewed for 
quality and feasibility;
•	 	 Research	approved	for	federal	funding	(e.g.,	NIH,	Department	
of Defense, Centers for Disease Control, Agency for 
Healthcare Research and Quality, Food and Drug Agency, 
Patient-Centered Outcomes Research Institute) that has gone 
through a peer-review process of its scientific validity and 
feasibility, including review of the research protocol;
•	 	 Research	approved	for	funding	by	industry,	foundations,	or	
other organizations, when the funding entity uses an adequate 




Such expectations notwithstanding, the IRB and/or 
Institutional Officials may forward to the SRC any protocol that 
otherwise potentially qualified for exempt and/or expedited 
handling, or was previously reviewed.
Roles of SRC Members
As embodied in an SRC, the process outlined in this document is 
envisioned as requiring six or more functions, including: a chair, 
a coordinator, medical/scientific reviewers (probably a minimum 
of three), a statistician, and content experts as needed. The chair 
and reviewers should have active research careers and have 
demonstrated scholarly accomplishments in the form of grants 
and publications. A chair and/or reviewer who is not actively 
engaged in research should be considered if he or she has a past 
history of conducting research. Involvement in institutional 
IRB and/or CTSA is beneficial, but not a requirement. Emphasis 
should be placed on having reviewers with diverse skill sets and 
clinical backgrounds. The following general criteria should be 
followed when considering candidates for SRC membership:
1.  Has the requisite expertise,
2.  Is not a research team member of the study subject to review,
3.  Has no conflict of interest,
4.  Is available to perform the review in a timely manner, and
5.  Is willing to undertake the task.
The roles of the proposed SRC members are as follow:
•	 	 Chair: The role of the chair (or his or her designee, with 
oversight) is to screen studies referred to the SRC by the 
IRB (or other referral source) to determine whether there 
is sufficient evidence of prior peer review and whether 
the protocol has all necessary components as defined in 
the Protocol Review Form (see Appendix 3). The chair leads 
the SRC meeting discussion, to ensure that all reviewers’ 
opinions are represented and, when necessary, helps resolve 
conflicting viewpoints. The chair participates in drafting 
communication on the SRC’s decision to PIs and reviews PIs, 
responses. In some circumstances, to help clarify concerns, the 
chair will meet with the PI to help clarify issues. If necessary, 
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the chair will direct the PI to consultative services to help with 
study design and protocol development.
•	 	 Coordinator: The coordinator works closely with SRC 
members, the IRB, and PIs to facilitate communication, ensure 
documentation of SRC communications, and distribute 
the outcome of the SRC’s deliberations. Additionally, the 
coordinator is responsible for scheduling and attending SRC 
meetings, taking minutes, and assisting the chair in drafting 
the report of the SRC’s decision for the PI.
•	 	 Medical Reviewer: A medical/scientific reviewer evaluates 
protocols for scientific merit using (but not limited to) 
criteria listed in the Protocol Review Form in Appendix 3. 
The reviewer attends SRC meetings and presents their review 
to the SRC for discussion.
•	 	 Statistician: A statistician reviews protocols and provides 
necessary feedback to ensure the appropriateness, adequacy, 
and alignment of study components. The components that 
are reviewed by the statistician include:
1. The study design including specific aims, approach, and 
methods,
2. The sample size and measurement design so that it has the 
power for the hypothesis(es) to be tested while controlling 
for inferential error rates,
3. The plans for ensuring data quality,
4. The statistical analysis plan, including plans for 
minimizing bias and handling of patient withdrawals 
and dropouts,
5. Identification of personnel essential for research success. 
The statistician also attends SRC meetings and presents 
his or her reviews to the SRC for discussion.
•	 	 Content Experts: In reviewing protocols, the SRC may need 
the assistance of faculty members, or other reviewers who 
have specific expertise relevant to the disease, condition, or 
research methods under consideration. Also, the SRC may 
need to go outside the institution to find a reviewer who 
has no conflict of interest. These questions may concern the 
relevance of the proposed study to the field, the relationship 
of the proposed study in reference to other ongoing research 
within the institution’s clinical program, or other technical 
issues beyond the expertise of SRC members. The role of the 
expert reviewer is to review the study in advance of the SRC 
meeting, to present their review during the meeting, and to 
address specific questions posed by the SRC. When a need for 
a content expert is identified by the SRC chair, the primary 
medical/scientific reviewer in consultation with the chair, or 
the SRC, the coordinator will contact the relevant department 
chair or division chief and ask for assistance in identifying 
a willing and available expert. If this results in a delay of 
more than a week, the PI should be notified that the SRC 
review will be delayed while an expert reviewer is identified. 
Once identified, the expert will be invited to the next SRC 
meeting, at which time the protocol will be discussed. The 
SRC recommendation will be communicated to the PI and 
the IRB. In the rare instance of an extended delay, the SRC 
may elect to review the protocol without the content reviewer 
and instead, forward questions to the PI.
SRC Application Process
A SRC review process is intended to ensure that human research 
protocols meet acceptable standards of scientific rigor and 
feasibility prior to IRB review. Institutions should have standard 
policies that govern coordination with the IRB that (1) facilitate 
the review process, and (2) allow the IRB access to the SRC review 
of protocols (see Appendix 4 for examples of communication 
from the SRC regarding protocol review status).
The medical reviewer ensures that while assessing protocols 
for scientific merit and operational feasibility based on the 
definitions given for the criteria within the form, at minimum, 
the core criteria on the Protocol Review Form are met (see 
Appendix 3). Each category on the form is to be categorized by the 
reviewer as: present/acceptable, present/not acceptable, or absent 
(see Appendix 3). To facilitate the review process, the reviewer’s 
assessment should be available for all members to view prior to 
meeting and discussed when the committee meets.




SRC where it is recorded and added to the list of protocols 
pending review.
•	 	 SRC	chair	or	an	institutional	screening	designee	conducts	
preliminary assessment of the study to determine whether 
it meets criteria for SRC review. The process should be 
transparent and logical to all involved.
•	 	 While	the	submitted	protocol	is	undergoing	assessment	to	
determine the path to review (see Figure A.1B), the PI should 




a statistical reviewer and medical/scientific reviewer(s). If 
necessary, review by a content expert also will be assigned.
•	 	 All	protocols	scheduled	for	SRC	review	should	be	available	for	
reviewers at least three business days prior to the meeting. All 
SRC members should be notified at that time and members 
told of their review assignments.
•	 	 All	protocols	will	be	reviewed	by	SRC	reviewers	based	on	
predetermined criteria to make a preliminary determination 
of scientific validity prior to meeting. Reviewers should use 
the Protocol Review Form (see Appendix 3) to make and 
record their assessment.
•	 	 All	communications	and	referencing	documents	during	the	
application process should be shared using a secure content 
management system.
SRC Process
Scientific Review Committee meetings are to be conducted 
regularly (e.g., weekly or biweekly) as long as there is a quorum 
and protocols for to review. The frequency of SRC meetings should 
be based on the number of protocols submitted for review in 
order to avoid delays in the review process. A quorum, may be 
defined as (at minimum) three medical/scientific reviewers, one 
statistical reviewer, the chair, and the coordinator being present. If 
there are protocols for the SRC to review and a meeting cannot be 
convened at the regularly scheduled time, an alternate time may 
be proposed and agreed upon within the same week. If at least 
three medical/scientific reviewers are not available, the meeting 
would be rescheduled. If the chair of the SRC is not available for 
a scheduled meeting, the chair would nominate a deputy chair 
for his or her absence.
Recommendations should be made by majority vote. If 
a reviewer is unable to attend, but has reviewed the relevant 
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information, their input would be considered in the deliberations of 
the meeting. However, only those members present for the majority 
of the meeting and present for critical deliberations would vote. 
There should be an attempt to achieve consensus in all decisions.
Potential SRC Actions
Potential SRC actions include:
1.  the protocol is returned to the PI for further action or 
revisions,
2.  the protocol is returned to the PI for further action for 
substantial revision, potentially with a recommendation to 
seek assistance from experts in study design, statistics, or 
other, or
3.  the protocol is forwarded to the IRB without further 
requirement for action by the PI.
Examples of SRC Correspondence
If a PI indicates that a protocol had prior peer review, he or she 
should provide supporting and related information prior to 
review. The PI should be contacted after the initial screening if 
there are any questions and/or it is determined that the protocol 
will undergo SRC review (see Notice of Scientific Review in 
Appendix 4). After the SRC convenes, recommendations should 
be sent to the PI and the IRB. The Notice of Scientific Review 
letter, recommendations, and committee meeting attendance 
would serve as meeting minutes. Minutes should be confidential 
and available to SRC and IRB members, and other institutional 
personnel as per institutional policy.
Example Response Process for SRC Reviews
If the protocol is returned to the PI for clarification or modification, 
the PI should submit an item-by-item response, along with 
applicable tracked-change documents, to the SRC office.
The revised protocol should be made available to all SRC 
assigned reviewers. The assigned reviewers and chair should 
determine if the revised protocol adequately addresses all concerns 
and questions of the SRC, if it needs to be discussed at the next 
convened SRC meeting, or if there are concerns remaining that 
need to be returned to the PI for further clarification and/or 
action. If the SRC requires further action by the PI, he or she 
should be notified immediately and should revise the protocol as 
necessary per the SRC comments and then re-submit for review. 
If appropriate, the PI should be given the opportunity to attend 
the reconvened SRC. At any time during this process, the PI may 
contact the SRC chair for assistance and guidance. This is noted 
in the Notice of Scientific Review letter (see Appendix 4) that is 
forwarded to the PI. The SRC chair may also contact the PI and/
or study coordinator at any point in the process for clarification 
or information if this would help review.
Conclusion
This document is the result of the CTSA Consortium SRC 
Consensus Working Group’s discussions, draft documents with 
iterative revisions, and final consensus. While an attempt to 
provide statements on a wide range of scientific and feasibility 
review, it is understood that this consensus document will leave 
some structures, processes, and procedures unspecified and left 
to the discretion of institutions. It is hoped that this report will 
provide a conceptual and procedural framework for SRC processes, 
criteria for selection for review, and criteria for the content review 
that can be applied in multiple institutions as a way to improve the 
quality and ethical compliance of their human participant research. 
The purpose of this consensus document is to provide a framework 
for rigorous scientific assessment in order to reinforce the mission 
of promoting research excellence in human participant research.
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Appendix 1. CTSA Consortium Scientific Review 
Committee (SRC) Consensus Working Group Information 
Technology (IT) Infrastructure Needs Assessment and 
Recommendations
Overview
A needs assessment was conducted September–December 2014 
with the SRC Consensus Working Group to determine best 
practices in IT infrastructure to support the project and data 
management of the recommended SRC process. The results of this 
assessment indicated that there is significant variation between 
both IT infrastructures and SRC processes among institutions. 
Variations in IT infrastructure ranged from institutions utilizing 
email and paper to maintain SRC and/or IRB processes, to others 
utilizing enterprise solutions such as, Click®, SharePoint, or 
similar home-grown electronic content/process management 
applications. Due to these variations, finding a single IT solution 
to support the key functions for all institutions conducting clinical 
research was not recommended.
Recommendations
Both a project management system to support the workflow of 
the SRC (e.g., communication between SRC staff, submission of 
protocols, time stamping key points in the workflow, etc.), and 
a data management system (e.g., to support data entry, quality 
control, and collection of evaluation metrics) was recommended 
by the Working Group. The following IT solutions provide both 
project and data management capabilities.
If institutions use Click® IRB to support the IRB review 
process, the suggested approach is to explore the “auxiliary 
review” functionality of the system. This would allow for 
communication between the IRB and SRC, as well as the ability to 
have all documents submitted and reviewed in one place. Adding 
an additional SRC module option could be explored, which would 
be an additional charge.
Institutions that already have an existing electronic, home-
grown project and data management system in place could create 
institutional policies and processes to collect the recommended 
metrics within their existing workflow.
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Appendix 2. Figure A.1 (A). Scientific Review at CTSA Institutions and (B). Scientific Review Committee (SRC) Review 
Process Combined
Figure A.1. (A) Scientific Review at CTSA Institutions. (B) Scientific Review Committee (SRC) Review Process Combined.
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Appendix 3. Scientific Review Committee Protocol Review and Monitoring Criteria Protocol Review Form
Scientific Reviewer Comments—(Page 1 of 3)
Title: ____________________________________________________________________________________________________
Principal Investigator: ____________________________________ Reviewer:___________________________________________
Type of Support (check all that apply): Type of funding and/or protocol support/assistance prior to SRC submission.
CTSA Pilot  ❑
CTSA K Awardee  ❑  Small industry support  ❑  Investigator-initiated  ❑
CTSA T Awardee  ❑   Large industry support  ❑  NIH or other federal support  ❑
CTSA funded  ❑    Multi-center  ❑   Study section review  ❑
Foundation support  ❑  Single-center  ❑   Protocol review  ❑




Translational: Study has clinical impact verses exploration.




Objectives: Clearly stated specific aims aligned with well-defined endpoints and appropriate study design.




Scientific Merit/Background and Rationale: Justification for conducting the study; results of similar or pilot data; current literature cited




Design: Cleary describes: how stated objectives will be achieved, methods to acquire data, and strategies to overcome anticipated 
barriers. Addresses randomization, minimization of bias, patient follow-up, and blinding (if applicable).




Eligibility Criteria: Specific inclusion/exclusion requirements and stratification factors (if applicable). 
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Outcome Characteristics and Endpoint Definitions: Clearly defined primary and secondary endpoints/outcomes.




Statistical Analysis and Sample Size: Appropriate and adequate study design statistical analysis plan. Prospective analysis plan, including 
sample size justification to achieve study objectives and plans to minimize missing data. 




Data Management: Practices and procedures in order to manage data analysis, quality, cleaning, and storage.




Principal Investigator and Study Site Qualifications and Resources: Has the necessary skills, experience, time, and resources to ensure 
that the study can be successfully completed, including identification of personnel to provide statistical computations and statistical 
expertise. A plan to register protocol with clinicaltrials.gov.
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Appendix 4. Examples of Communication from SRC: 
Protocol Review Status
Example One: Notice of Review
This email is to inform you that your new protocol submission, 
IRB #____, entitled “________,” was forwarded to Scientific 
Review Committee (SRC) Chair for possible review. Once the 
Chair has determined whether SRC review is necessary, we will 
inform you of the decision. Please refer to our website for more 
information on the SRC and IRB processes and feel free to contact 
our office with any questions you may have.
Example Two: Letter to Inform PI of Study Selection
This email is to inform you that your new protocol submission, 
IRB # ____, entitled “_________,” has been selected to be 
reviewed by the institutional Scientific Review Committee (SRC). 
It is scheduled for review by the SRC on [date].
The SRC was established to reinforce the institutional mission 
in promoting research excellence. The SRC reviews selected 
clinical research proposals to ensure that they meet an acceptable 
standard of scientific rigor and merit prior to IRB review. For 
more information about the SRC, please visit the IRB website.
You will be notified about the outcome of SRC review of your 
protocol and will be sent communication regarding any necessary 
changes to the protocol.
If you have administrative questions regarding this matter 
please contact me at (XXX) XXX-XXXX.
